Pharmaceutical industry experts said the US move had come as a boon for the Indian drug exporters as the law could clear the alleged doubts on the quality and the genuineness of Indian pharmaceutical and raw material products.
In 2000, when Internet companies across the world were shutting shop, this start-up refused to join the crowd and continued with its operations despite the losses -- a move that defied conventional business logic at that time.
Pirates won't have it easy any more as the organised market gets savvy.
The Human Resources Ministry is seriously attempting to manufacture laptops at almost half the price of the cheapest mobile -$10 or just Rs 420.
The $66 million (Rs 272.8 crore) Leiner Health Products is likely to sue DRL for the early divorce (the agreement has lasted only four years) from the alliance.
The world's largest manufacturer of healthcare products, Johnson & Johnson, is making India a global hub of its research and development as it looks to ramp up its pharmaceutical business in the country.
Initial fears of Internet access charges rising by 6-12 per cent following the Telecom Regulatory Authority of India recommendations to impose an annual licence fee for Internet Service Providers appear to be unfounded.
The increasing number of generic players tapping the US market for known molecules has resulted in pricing pressures and lean margins.
The domestic market for business process outsourcing - which is growing at a compound annual growth rate of 50 per cent - is catching the attention of BPO companies that have traditionally catered to the international market.
A start-up by three friends with Angel investment of Rs 1.5 crore, NautankiTV has close to 40 per cent of its users from the US and UK.
D Aravindakshan was the managing director of Kerala State Drugs and Pharmaceuticals at Alleppey for many years before taking over as the head of Agastya Biopharma
In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
In comparison, Indian companies received only 23 out of 139 final approvals (16.54 per cent) in the corresponding period in 2006.
The domestic business intelligence sector is fast outgrowing its infancy, thanks to an increase in mergers and acquisitions.
However, projections made over the last few years indicate a compound annual growth rate (CAGR) of 80-90 per cent. Research firm TPI believes this is "not easily achievable".
The Bangalore-based Himalaya Herbal Healthcare has struck strategic alliances with leading retail chains in its main export markets such as the US, Singapore and Malaysia.
Paris-based IT major Capgemini is scouting for three more acquisitions amounting to over $1 billion (around Rs 4,300 crore or Rs 43 billion). It is looking at the business process outsourcing (BPO), product engineering and local consulting space.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
The salaries of hardware engineers in the Indian information technology industry have nearly doubled over the last two years and yet the exodus to software continues, according to an Elixir Web Solutions survey.
A recent court ruling in the US on allowing the declaratory judgment provision in the US patent law has come as a boost to Indian pharmaceutical companies such as Ranbaxy, Dr Reddy's, Sun Pharma and Lupin.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances